Two New Weight-Loss Peptides — Which One Makes More Sense?

The GLP-1 peptide space has exploded over the past two years, and two compounds are generating more buzz than almost anything else: retatrutide and mazdutide. Both deliver serious results in clinical trials, but they work through fundamentally different mechanisms. One hits three receptors; the other hits two. That distinction matters more than it sounds — it affects how fast weight drops, what side effects show up, and who benefits most.

Here is a clear-eyed comparison of each compound, what the data actually shows, and how to think about choosing between them.

Retatrutide: The Triple GLP-1/GIP/Glucagon Agonist

Retatrutide activates three receptor types simultaneously: GLP-1, GIP, and the glucagon receptor. This triple-agonist mechanism is what sets [[Retatrutide|11]] apart from nearly everything else in development right now.

Each receptor pulls a different metabolic lever:

• GLP-1 — suppresses appetite, slows gastric emptying, enhances insulin secretion
• GIP — amplifies the insulin response, improves lipid metabolism, may attenuate GLP-1-induced nausea
• Glucagon — increases energy expenditure, drives hepatic fat breakdown, boosts thermogenesis

The glucagon component is the real differentiator. It essentially revs up the metabolic engine, forcing the body to burn more calories even at rest. In the phase 2 trial published in the New England Journal of Medicine (2023), participants on the highest retatrutide dose lost an average of 24.2% of their body weight over 48 weeks. As of today, that remains one of the highest weight-loss figures reported for any investigational peptide.

The speed of onset is notable too. Many participants reported meaningful appetite suppression within the first two weeks of treatment. Unlike some GLP-1 agents where you spend weeks titrating up before noticing much, retatrutide tends to show its hand early — and the weight-loss curve keeps trending downward without the plateau that sometimes hits around month four or five with other compounds.

Retatrutide Side Effect Profile

Side effects are broadly consistent with the GLP-1 class: nausea, diarrhea, decreased appetite. One interesting nuance — the GIP component appears to partially buffer the nausea that typically accompanies GLP-1 stimulation. That said, at higher doses, gastrointestinal symptoms were more frequent than what you typically see with semaglutide.

For those who prefer a simpler injection experience, the [[Retatrutide Pen|38]] offers a pre-filled format that simplifies dosing and makes the weekly shot less of a hassle.

Mazdutide: The Dual GLP-1/Glucagon Agonist

[[Mazdutide|13]] is developed by Innovent Biologics, a Chinese biotech company. It activates GLP-1 and glucagon receptors but skips GIP entirely. Think of it as sitting midway between classic GLP-1 monoagonists (semaglutide, liraglutide) and the triple agonist retatrutide.

Key characteristics:

• GLP-1 activation — standard appetite suppression and glycemic control
• Glucagon activation — enhanced energy expenditure and lipolysis, similar to what retatrutide provides
• No GIP component — potentially different side effect profile and metabolic response

In phase 2b trials (2024 data, predominantly Chinese patient population), mazdutide at the 9 mg dose produced approximately 16-18% body weight reduction over 48 weeks. That falls short of retatrutide but sits roughly on par with tirzepatide and above semaglutide 2.4 mg.

What Mazdutide Does Well

Where mazdutide particularly shines is liver fat reduction. Trial data show significant decreases in hepatic steatosis (fatty liver disease), which makes biological sense — the glucagon receptor has a direct role in hepatic lipid metabolism, and activating it helps clear fat from the organ.

The safety profile is generally favorable. GI side effects are present but, based on available data, tolerability appears comparable to semaglutide and somewhat better than retatrutide at higher doses.

Head-to-Head Comparison: Triple vs Dual Agonist

Parameter	Retatrutide (Triple)	Mazdutide (Dual)
Receptors	GLP-1 + GIP + Glucagon	GLP-1 + Glucagon
Weight loss (48 wk)	Up to 24.2%	16-18%
Onset speed	Noticeable from week 2	Gradual build-up
Liver fat impact	Significant reduction	Pronounced steatosis decrease
GI side effects	Moderate to marked	Moderate
Development stage	Phase 3 (Eli Lilly)	Phase 3 (Innovent)
Injection frequency	Once weekly	Once weekly
GIP component	Yes — improves lipid profile	No

When Retatrutide Is the Better Fit

Retatrutide tends to be the stronger choice when:

• Maximum weight loss is the primary goal
• You want to see results as quickly as possible
• You are dealing with metabolic syndrome and need broad metabolic impact
• You are comfortable managing more pronounced side effects for a better outcome
• You have already used GLP-1 monoagonists (semaglutide, liraglutide) and hit a plateau

When Mazdutide Is Worth Considering

Mazdutide may be the better option if you:

• Want a balance between efficacy and tolerability
• Have non-alcoholic fatty liver disease (NAFLD/MAFLD) as a primary concern
• Experienced significant GI side effects with other GLP-1 drugs
• Prefer a gentler ramp-up

What the Research Actually Shows — Important Context

No head-to-head trial comparing retatrutide and mazdutide has been conducted. Every number cited above comes from different clinical programs, with different patient populations and study designs. Mazdutide trials enrolled predominantly Asian participants, where metabolic responses to peptide therapies can differ from European cohorts. Cross-trial comparisons are useful for orientation but should not be treated as definitive.

Retatrutide is developed by Eli Lilly — the same company behind tirzepatide (Mounjaro/Zepbound). Mazdutide comes from Innovent Biologics, which has a partnership with Eli Lilly on other molecules. Both compounds are in phase 3 trials, with final data expected over the next one to two years.

Practical Considerations

Both peptides are administered subcutaneously once per week. The standard approach involves gradual dose titration to minimize gastrointestinal side effects.

A typical retatrutide titration schedule looks like this:

• Weeks 1-4: starting dose
• Weeks 5-8: intermediate dose
• Week 9 onward: maintenance dose

Storage conditions are standard: refrigerate at 2-8°C, protect from direct sunlight. Shelf life is 90 days from the date of manufacture. Do not freeze.

Combining With Other Approaches

Neither retatrutide nor mazdutide is a standalone solution. Optimal outcomes come from pairing the peptide with:

• Moderate caloric deficit (300-500 kcal below maintenance)
• Resistance training to preserve lean mass
• Adequate protein intake (1.6-2.2 g per kg of body weight)
• Sufficient sleep (7-9 hours per night)

The peptides make it dramatically easier to maintain a caloric deficit by crushing appetite, but they do not replace the fundamentals of sensible nutrition and activity.

Where to Buy Retatrutide and Mazdutide

Both compounds are available through Peptex with shipping across the EU. If you have questions about choosing between retatrutide and mazdutide, dosing protocols, or anything else — reach out to us and the team will help you find the right fit.

This article is provided for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any peptide regimen. Clinical trial results were obtained under controlled conditions and individual outcomes may vary.